Gergen Mark J 4
4 · Poseida Therapeutics, Inc. · Filed Mar 2, 2023
Insider Transaction Report
Form 4
Gergen Mark J
DirectorExecutive Chairman
Transactions
- Award
Employee Stock Option (Right to Buy)
2023-03-01+364,060→ 364,060 totalExercise: $5.35Exp: 2033-02-28→ Common Stock (364,060 underlying) - Award
Common Stock
2023-03-01+269,586→ 601,610 total
Footnotes (3)
- [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
- [F2]Includes 1,710 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2021.
- [F3]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.